Poly ADP-ribose polymerase inhibitors (PARPi) are used for patients with advanced prostate cancer bearing alterations in homologous recombination repair (HRR) genes. We sought to characterize HRR gene ...
(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...
Identification of variants influences treatment decisions. Inhibitors of the poly-ADP-ribose polymerase (PARP) system, a pathway for repairing single-stranded DNA breaks, are recommended for tumors ...
"Men with these known variants should be counseled on the increased risk of prostate cancer, and I would recommend that they undergo regular PSA screening…Of course there are many other factors that ...
Phase 3 TALAPRO-3 results show that talazoparib plus enzalutamide significantly improves radiographic progression-free survival in HRR-mutated metastatic castration-sensitive prostate cancer, ...
Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair. If you have the appropriate software installed, you can download article citation data to the citation manager of your choice.
A new international study has found that combining two cancer medicines may significantly slow the growth of a dangerous form ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results